RPLP0

Large ribosomal subunit protein uL10 (60S aci · P05388 · RPLP0 on Sugi Atlas →

3,677 patent compounds predicted against RPLP0, 1,927 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPLP0 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Liraglutide on ER Stress in Obese Patients With Type 2 Diabetes	PHASE4	UNKNOWN
Management of Retinitis Pigmentosa Via Combination of Wharton's Jelly-derived Mesenchymal Stem Cells and Magnovision	PHASE3	COMPLETED
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Esophageal Cancer	PHASE1/PHASE2	COMPLETED
Histocompatibility Leukocyte Antigen (HLA)-A*0201 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer	PHASE1/PHASE2	COMPLETED
Mobilization of Stem Cells With G-CSF for Collection From Patients With Diamond-Blackfan Anemia	PHASE2	COMPLETED
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Gastric Cancer	PHASE1/PHASE2	COMPLETED
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors	PHASE1/PHASE2	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Human Leukocyte Antigen (HLA) - A*2402 Restricted Peptide Vaccine Therapy in Patients With Advanced Gastric Cancer	PHASE1	COMPLETED
Combination of Chemoradiation Therapy and Epitope Peptide Vaccine Therapy in Treating Patients With Esophageal Cancer	PHASE1	UNKNOWN
Vaccine Therapy in Treating Patients With Chronic Myelogenous Leukemia	PHASE1	COMPLETED
UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies	PHASE1	RECRUITING
Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer	PHASE1	SUSPENDED
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED
Mitoquines in COPD	nan	UNKNOWN
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Role of SF3B1 Mutation in Assessment of Acute and Chronic Lymphatic Leukemia	nan	NOT_YET_RECRUITING
Longitudinal Study of the Porphyrias	nan	RECRUITING
Exercise on Expression of Heat Shock Protein 70 in Arterial Risk	nan	COMPLETED
Predictive Role of New Biomarkers for Hypersensitive Patients to Radiation in Breast Cancer (BIORISE)	nan	ACTIVE_NOT_RECRUITING
Cytomegalovirus (CMV) MicroRNA Expression in Vivo and Immune Evasion Correlates	nan	COMPLETED
Intermittent Fasting for Pancreatitis	nan	NOT_YET_RECRUITING
Umbilical Cord Blood Proteomic Analysis and Neonatal Brain Injury	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a RPLP0 binder may also engage these)

Protein	Name	Similarity
Q95140	—	1.000	Q95140 →
P14869	—	1.000	P14869 →
G1SPK4	—	1.000	G1SPK4 →
P19945	—	1.000	P19945 →
Q29214	—	1.000	Q29214 →
P47826	—	0.999	P47826 →
Q8NHW5	—	0.999	Q8NHW5 →
Q9DG68	—	0.983	Q9DG68 →
Q9PV90	—	0.960	Q9PV90 →
Q90YX1	—	0.954	Q90YX1 →
Q2VIR3	—	0.940	Q2VIR3 →
Q2KHU8	—	0.939	Q2KHU8 →
C9WPN6	—	0.938	C9WPN6 →
Q9Z0N2	—	0.937	Q9Z0N2 →
P42794	—	0.937	P42794 →
P81795	—	0.935	P81795 →
Q4R5I3	—	0.935	Q4R5I3 →
A2YDY2	—	0.935	A2YDY2 →
P46287	—	0.935	P46287 →
Q5ZMS3	—	0.935	Q5ZMS3 →
P20461	—	0.935	P20461 →
Q0DK10	—	0.935	Q0DK10 →
F1QGW6	—	0.934	F1QGW6 →
G1TU13	—	0.932	G1TU13 →
Q5R797	—	0.932	Q5R797 →
P41091	—	0.932	P41091 →
A5PK63	—	0.932	A5PK63 →
RPS17	Small ribosomal subunit protein eS17	0.932	landscape →
Q90YQ6	—	0.932	Q90YQ6 →
P04644	—	0.931	P04644 →